With recent approvals of immune checkpoint inhibitors for the treatment of R/M HNSCC, effects of adding PI3K inhibitors to immune checkpoint inhibitors will be further explored. The gene discussed is PIK3CB; the disease is head and neck squamous cell carcinoma.